Philips Teams with Organon on Biomarker ID, Validation, But Remains Quiet on Dx M&A Plans | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Marking another step in its evolving molecular diagnostics strategy, Royal Philips Electronics last week signed a deal to collaborate with Dutch biotech firm Organon to discover and validate biomarkers for psychiatric disorders and cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.